Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Extrawell Pharmaceutical HoldingsHKSE:00858 EBITDA Margin % is -2,165.63% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Extrawell Pharmaceutical Holdings ranks worse than 97.4% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Extrawell Pharmaceutical Holdings EBITDA Margin % Related Terms
Extrawell Pharmaceutical Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extrawell Pharmaceutical Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Extrawell Pharmaceutical Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extrawell Pharmaceutical Holdings (HKSE:00858) has a EBITDA Margin % of -2,165.63% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Extrawell Pharmaceutical Holdings and its competitors. According to the industry distribution chart, Extrawell Pharmaceutical Holdings ranks #936 out of 961 companies in the Drug Manufacturers industry, placing it in the top 97.4%.
Is Extrawell Pharmaceutical Holdings' EBITDA Margin % too high?
Extrawell Pharmaceutical Holdings' current EBITDA Margin % is -2,165.63%. Based on the distribution chart, Extrawell Pharmaceutical Holdings ranks #936 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Extrawell Pharmaceutical Holdings' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Extrawell Pharmaceutical Holdings ranks #936 out of 961 companies for EBITDA Margin %. This places Extrawell Pharmaceutical Holdings in the lower half of its industry. The industry median EBITDA Margin % is 11.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.88, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Extrawell Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extrawell Pharmaceutical Holdings's current EBITDA Margin % is -2,165.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 68% above its estimated fair value. The current EBITDA Margin % is -2,165.63%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current EBITDA Margin % is -2,165.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00858 has been successfully added to your 
